Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
Rhea-AI Summary
Allergan Aesthetics (NYSE: ABBV) partnered with entrepreneur Erin Lichy to share her Natrelle® breast augmentation journey on social media, aiming to normalize conversations about aesthetic surgery and support patient education.
The release highlights Natrelle®'s 50-year heritage, a 10-year clinical safety profile, implant options, and a nationwide Faces of Natrelle® testimonial program.
Positive
- None.
Negative
- None.
News Market Reaction – ABBV
In the Apr 14 session, ABBV gained 1.84%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Pain license deal | Positive | -0.7% | Exclusive global license agreement with Haisco for multiple pain compounds. |
| Apr 08 | Brand grant program | Positive | +2.5% | BOTOX Cosmetic opens Confidence Collective grants and support for 250 women entrepreneurs. |
| Apr 07 | Training center launch | Positive | -0.1% | Opening of Allergan Medical Institute Austin training center for aesthetic providers. |
| Mar 31 | CoolSculpting promo | Positive | +2.0% | Fourth annual CoolMonth with CoolSculpting discounts and social giveaways. |
| Mar 31 | CoolMonth correction | Positive | +2.0% | Correction release reiterating details of CoolMonth discounts and promotions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Allergan Aesthetics promotional and program news often coincided with positive or modestly positive moves, while a larger R&D licensing deal saw a slight negative reaction, suggesting varied price responses across commercial and pipeline headlines.
Over the last few weeks, AbbVie-related news has focused heavily on Allergan Aesthetics brand-building and partnerships. CoolSculpting® CoolMonth promotions on Mar 31 and the BOTOX® Cosmetic Confidence Collective grant program on Apr 8 coincided with gains of ~2–2.5%. The new AMI Austin training center on Apr 7 saw only a small move, while the Apr 13 Haisco pain-license agreement linked to substantial milestones coincided with a -0.71% reaction. Today’s Natrelle® campaign continues this aesthetics-marketing trend rather than shifting core fundamentals.
Key Terms
breast implant–associated anaplastic large cell lymphoma medical
bia-alcl medical
autoimmune diseases medical
chemotherapy medical
body dysmorphic disorder medical
boxed warning regulatory
mammography medical
capsular contracture medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- The entrepreneur and mother of four shares her breast augmentation journey, from consultation to post-op, with Natrelle® breast implants.
- As a champion of authenticity, Lichy hopes her transparency will help normalize the conversation around breast surgery.
"Motherhood and breastfeeding changed my body in ways I didn't fully expect, and I found myself wanting to feel more like me again," said Erin Lichy. "I didn't originally consider breast implants because I was looking for an understated result, but after sharing my aesthetic goals with board-certified plastic surgeon Dr. Ira Savetsky, we chose Natrelle® implants. It was a very educational conversation. We talked about projection, profile, the safety of the implant and how they would look on my body. I'm thrilled with my results, and I'm sharing my experience to help other women feel more confident to explore their own options."
As part of her partnership with Natrelle®, Lichy will be sharing her experience from consultation to post-op across her social media channels.
"Every woman's aesthetic journey is unique. Erin's transparency and willingness to share her story fosters connection for other women," said Nicole Mowad-Nassar, President, Global Allergan Aesthetics and Senior Vice President, AbbVie. "Honest conversations are the first step in helping women who may be interested in breast augmentation feel empowered to schedule a consultation and learn more."
With the most comprehensive range of smooth breast implant options, Natrelle® is built on a 50-year legacy of innovation in breast aesthetics and offers five profiles and three gummy gel cohesivities1, giving board-certified plastic surgeons the flexibility to tailor each patient's desired results. Natrelle® breast implants have a 10-year clinical safety profile backed by a rigorous clinical trial.1 As more women seek clear, credible information about aesthetic procedures, Natrelle® continues to prioritize patient education and close partnership with board-certified plastic surgeons.1
Patients who are inspired by Erin's story can continue fueling the transparent conversation by entering the Faces of Natrelle® Testimonial Program. The nationwide initiative invites women who have undergone breast augmentation or reconstruction with Natrelle® implants to share their personal experiences through photos, videos, and written testimonials for a chance to be featured on the brand's social media platforms, and website.
To learn more about eligibility and how to submit your story, visit:
- Augmentation Patients: faces.natrelle.com/augmentation
- Reconstruction Patients: faces.natrelle.com/reconstruction
To learn more about treatment with Natrelle® or find a provider, please visit natrelle.com, and follow along on Instagram @natrellebreastaugmentation and @natrellebreastreconstruction.
Natrelle® Breast Implants IMPORTANT SAFETY INFORMATION AND APPROVED USES
Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery.
Breast implants have been associated with the development of a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined. Some patients have died from BIA-ALCL.
Patients receiving breast implants have reported a variety of systemic symptoms, such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.
Who can get breast implants?
Natrelle® Breast Implants are approved for the following:
- Breast augmentation for women at least 22 years old for silicone-filled implants and for women at least 18 years old for saline-filled implants. Breast augmentation includes primary breast augmentation to increase the breast size and revision surgery to correct or improve the result of a primary breast augmentation
- Breast reconstruction. This includes primary breast reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. This also includes revision surgery to correct or improve the result of a primary breast reconstruction
Who should NOT get breast implants?
Breast implant surgery should NOT be performed in:
- Women with active infection anywhere in their body
- Women with existing cancer or precancer of their breast who have not received adequate treatment for those conditions
- Women who are currently pregnant or nursing
What should I tell my doctor?
Tell your doctor if you have any of the following conditions, as the risks of breast implant surgery may be higher:
- Autoimmune diseases (eg, lupus and scleroderma)
- A weakened immune system (eg, taking medications to decrease the body's immune response)
- Planned chemotherapy or radiation therapy following breast implant placement
- Conditions or medications that interfere with wound healing and blood clotting
- Reduced blood supply to breast tissue
- Clinical diagnosis of depression or other mental health disorders, including body dysmorphic disorder and eating disorders
- Those with a diagnosis of depression or other mental health disorders should wait for resolution or stabilization of these conditions prior to undergoing breast implantation surgery
What else should I consider?
- There is a Boxed Warning for breast implants. Please see bold text at beginning
- Many changes to your breasts following implantation are irreversible. If you later choose to have your implants removed and not replaced, you may experience dimpling, puckering, wrinkling, or other cosmetic changes, which may be permanent
- Breast implantation is likely not a one-time surgery. The longer implants are in place, the greater the potential risk for complications. You will likely need additional surgeries on your breasts due to complications or unacceptable cosmetic results. Thus, you should also consider the complication rates for later (revision) surgery since you may experience these risks in the future
- Cancer treatments and surgery will affect the outcome and timing of breast reconstruction
- Breast implants may affect your ability to breastfeed, either by reducing or eliminating milk production
- Rupture of a silicone-filled breast implant is most often silent. Even if you have no symptoms, you should have your first ultrasound or MRI at 5 to 6 years after your initial implant surgery and then every 2 to 3 years thereafter regardless of whether your implants are for augmentation or reconstruction. If you have symptoms of or uncertain ultrasound results for breast implant rupture, an MRI is recommended. Additional imaging may be required depending on your medical history and status. The health consequences of a ruptured silicone gel-filled breast implant have not been fully established
- Routine screening mammography for breast cancer will be more difficult, and implants may rupture during the procedure. Perform self-examination every month for cancer screening and ask your surgeon to help you distinguish the implant from your breast tissue. Lumps, persistent pain, swelling, hardening, or changes in implant shape should be reported to your surgeon and possibly evaluated with imaging
What are key complications with breast implants?
Key complications include reoperation, implant removal with or without replacement, implant rupture with silicone-filled implants, implant deflation with saline-filled implants, and capsular contracture (severe scar tissue around the implant). Other complications include breast pain, swelling, asymmetry, wrinkling/rippling, implant malposition nipple complications, hypertrophic scarring, and implant palpability/visibility.
Talk to your doctor about other complications.
For more information, see the patient brochures at https://www.rxabbvie.com.
To report a problem with Natrelle® Breast Implants, please call Allergan® at 1-800-624-4261.
The sale and distribution of Natrelle® Breast Implants is restricted to licensed physicians who provide information to patients about the risks and benefits of breast implant surgery.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
References:
- Natrelle® Data on file 2023 – 2024. Accessed April 10, 2026.
© 2026 AbbVie. All rights reserved. NATRELLE and its design are trademarks of Allergan, Inc., an AbbVie company.
Contacts:
Allergan Aesthetics Media:
Ember Garrett
+1 (949) 413-6091
Garrett_ember@allergan.com
AbbVie Investors:
Liz Shea
+1 (847) 935-2211
Liz.Shea@abbvie.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/erin-lichy-gets-real-about-her-natrelle-breast-augmentation-302741658.html
SOURCE AbbVie